-
Something wrong with this record ?
Tumor markers as useful predictors of survival rate after exploratory laparotomy for liver malignancies
Liska V, Holubec L, Treska V, Skalicky T, Sutnar A, Topolcan O, Kormunda S, Finek J
Language English Country Greece
Grant support
NR7905
MZ0
CEP Register
NR8301
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
PubMed
17649789
Knihovny.cz E-resources
- MeSH
- CA-19-9 Antigen blood MeSH
- Financing, Organized MeSH
- Kaplan-Meier Estimate MeSH
- Carcinoembryonic Antigen blood MeSH
- Laparotomy MeSH
- Humans MeSH
- Survival Rate MeSH
- Biomarkers, Tumor analysis MeSH
- Liver Neoplasms blood mortality pathology MeSH
- Peptides blood MeSH
- Pilot Projects MeSH
- Prognosis MeSH
- Thymidine Kinase blood MeSH
- Tissue Polypeptide Antigen blood MeSH
- Check Tag
- Humans MeSH
BACKGROUND: Tumor markers are used for the prediction of relapse and in determining the effect of postoperative or post-oncological therapy as a standard component of follow-up. Metastatic processes of the liver and primary malignancies of the liver and gall bladder are very common in the European population. The aim of this study was to demonstrate the behaviour of malignancy in patients who have not undergone surgical therapy and to study serum levels of the monitored tumor markers in relation to the life expectancy of these patients. PATIENTS AND METHODS: The Log-rank test and Wilcoxon test were used for statistical evaluation. Survival was computed using the Kaplan-Meier method. Serum levels of the tumor markers conventionally used in clinical practice in patients with gastrointestinal tumors (CEA, CA19-9, C724) and the markers of the proliferation activity in malignancy (TK, TPA, TPS) were studied. RESULTS: One hundred and nine patients who underwent exploratory laparotomy without any surgical therapy between September 1999 and June 2005 were studied. For patients with a serum level of CEA, CA19-9 and CA72-4 that was higher than the calculated cut-off hazard ratios of early death were respectively 3-, 5- and 9-fold higher than for patients with serum levels of the same tumor markers below the calculated cut-off. Preoperative serum levels of proliferative tumor markers (TK, TPA and TPS) were not statistically significant for the prediction of early death. CONCLUSION: The results of the pilot study suggest the importance of tumor markers for the prediction of the short-term survival rate. These markers could be used to supplement classic clinical, laboratory and radiodiagnostic parameters. It would be very helpful for the planning of palliative oncological therapy for patients with liver malignancies who cannot be treated by surgical therapy.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10001057
- 003
- CZ-PrNML
- 005
- 20131010100252.0
- 008
- 100118s2007 gr e eng||
- 009
- AR
- 035 __
- $a (PubMed)17649789
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Liška, Václav, $d 1978- $7 xx0073943
- 245 10
- $a Tumor markers as useful predictors of survival rate after exploratory laparotomy for liver malignancies / $c Liska V, Holubec L, Treska V, Skalicky T, Sutnar A, Topolcan O, Kormunda S, Finek J
- 314 __
- $a DepartmentS of Surgery, University Hospital in Pilsen, Czech Republic
- 520 9_
- $a BACKGROUND: Tumor markers are used for the prediction of relapse and in determining the effect of postoperative or post-oncological therapy as a standard component of follow-up. Metastatic processes of the liver and primary malignancies of the liver and gall bladder are very common in the European population. The aim of this study was to demonstrate the behaviour of malignancy in patients who have not undergone surgical therapy and to study serum levels of the monitored tumor markers in relation to the life expectancy of these patients. PATIENTS AND METHODS: The Log-rank test and Wilcoxon test were used for statistical evaluation. Survival was computed using the Kaplan-Meier method. Serum levels of the tumor markers conventionally used in clinical practice in patients with gastrointestinal tumors (CEA, CA19-9, C724) and the markers of the proliferation activity in malignancy (TK, TPA, TPS) were studied. RESULTS: One hundred and nine patients who underwent exploratory laparotomy without any surgical therapy between September 1999 and June 2005 were studied. For patients with a serum level of CEA, CA19-9 and CA72-4 that was higher than the calculated cut-off hazard ratios of early death were respectively 3-, 5- and 9-fold higher than for patients with serum levels of the same tumor markers below the calculated cut-off. Preoperative serum levels of proliferative tumor markers (TK, TPA and TPS) were not statistically significant for the prediction of early death. CONCLUSION: The results of the pilot study suggest the importance of tumor markers for the prediction of the short-term survival rate. These markers could be used to supplement classic clinical, laboratory and radiodiagnostic parameters. It would be very helpful for the planning of palliative oncological therapy for patients with liver malignancies who cannot be treated by surgical therapy.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a antigen CA-19-9 $x krev $7 D018395
- 650 _2
- $a karcinoembryonální antigen $x krev $7 D002272
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a laparotomie $7 D007813
- 650 _2
- $a nádory jater $x krev $x mortalita $x patologie $7 D008113
- 650 _2
- $a peptidy $x krev $7 D010455
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a thymidinkináza $x krev $7 D013937
- 650 _2
- $a tkáňový polypeptidový antigen $x krev $7 D019396
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 700 1_
- $a Holubec, Luboš, $d 1941- $7 skuk0003095
- 700 1_
- $a Třeška, Vladislav, $d 1957- $7 jn20000402436
- 700 1_
- $a Skalický, Tomáš, $d 1965- $7 xx0017169
- 700 1_
- $a Sutnar, Alan $7 xx0081862
- 700 1_
- $a Topolčan, Ondřej, $d 1943- $7 jn20000402383
- 700 1_
- $a Kormunda, Stanislav $7 xx0103970
- 700 1_
- $a Fínek, Jindřich, $d 1957- $7 xx0026897
- 773 0_
- $w MED00000478 $t Anticancer research $g Roč. 27, č. 4A (2007), s. 1887-1891 $x 0250-7005
- 910 __
- $a ABA008 $b x $y 8 $z 0
- 990 __
- $a 20100114083259 $b ABA008
- 991 __
- $a 20131010100815 $b ABA008
- 999 __
- $a ok $b bmc $g 704674 $s 567237
- BAS __
- $a 3
- BMC __
- $a 2007 $b 27 $c 4A $d 1887-1891 $i 0250-7005 $m Anticancer research $x MED00000478
- GRA __
- $a NR7905 $p MZ0
- GRA __
- $a NR8301 $p MZ0
- LZP __
- $a 2010-b1/vtme